Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Mifepristone in Advanced Breast Cancer
NCT03225547Phase 2Terminated
- Sponsor
- University of Chicago
- Start
- Feb 2018
- Primary completion
- Sep 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab, mifepristone in breast cancer, sponsored by University of Chicago. Started Feb 2018; status: terminated.
02
Drugs
pembrolizumabmifepristone
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03225547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03225547.